[go: up one dir, main page]

US8163789B2 - Selective and dual-action p53/MDM2/MDM4 antagonists - Google Patents

Selective and dual-action p53/MDM2/MDM4 antagonists Download PDF

Info

Publication number
US8163789B2
US8163789B2 US12/106,280 US10628008A US8163789B2 US 8163789 B2 US8163789 B2 US 8163789B2 US 10628008 A US10628008 A US 10628008A US 8163789 B2 US8163789 B2 US 8163789B2
Authority
US
United States
Prior art keywords
mdm2
alkyl
optionally substituted
compounds
mdm4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/106,280
Other languages
English (en)
Other versions
US20080280769A1 (en
Inventor
Alexander Doemling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Priority to US12/106,280 priority Critical patent/US8163789B2/en
Assigned to UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION reassignment UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOEMLING, ALEXANDER
Publication of US20080280769A1 publication Critical patent/US20080280769A1/en
Application granted granted Critical
Publication of US8163789B2 publication Critical patent/US8163789B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Definitions

  • the occurrence of many human cancers can be linked to impaired nonfunctional p53 protein.
  • the p53 protein is a tumor suppressor encoded by a gene whose disruption is associated with about 50% of all cancers.
  • the p53 protein acts as a checkpoint in the cell cycle, either preventing or initiating programmed cell death. Additionally, p53 protein is also involved in the development of tumors that have become resistant to treatment. It therefore appears that p53 plays a key role in the controlling the progression of cancer.
  • p53 is a transcription factor whose ability to initiate programmed cell death is most often repressed in cancer.
  • the oncoprotein MDM2 is believed to be the main negative regulator of this protein.
  • MDM2/p53 association has been implicated to play a role in drug resistance that has become a major problem in anti-cancer therapy.
  • the present invention provides methodology for selecting compounds that are capable of antagonizing the p53/MDM2 interaction. Additionally, the invention provides a strategy for overcoming negative regulator-dependant cancer resistance in vitro, cell-based, and xenograft models. Of the several classes of antagonists have been developed, the most prominent and best investigated are the nutlins.
  • MDM4 p53-binding protein
  • MDMX p53-binding protein
  • dual-action p53/MDM2/MDM4 antagonists “could be used to treat 2,000,000-3,000,000 new cancers each year, and so might represent an important class of anti-cancer drugs, assuming that their therapeutic index is acceptable.”
  • Toledo & Wahl (2006) See Wahl et al., Nat. Rev. Cancer (2006), 6, 909.
  • a method for identifying a compound that disrupts protein-protein interaction.
  • the inventive method comprises (A) identifying a region of a first protein that interacts with a binding region a second protein using high resolution structural data; (B) incorporating a fragment of the identified region from step (A) into a database comprising multi-component reaction scaffolds to generate a library of molecules that incorporate the fragment; (C) docking the molecules from step (B) into a high resolution structure of the second protein; and (D) analyzing the results from step (C) to identify a compound that disrupts protein-protein interaction.
  • the invention provides a method for screening compounds that antagonizes MDM2/p53 or MDM4/p53 complex.
  • the method of the invention comprises (A) contacting the complex with a compound to be screened and (B) obtaining a NMR of the complex in (i) the presence and (ii) absence of the compound, such that changes in the NMR spectrum are revealed, where the spectral changes result from a disruption the complex by the compound.
  • the MDM2/p53 or MDM4/p53 antagonist is an imidazole, an imidazolidine, a ⁇ -lactam, a tetrahydroquinoline, a 2-aminomethyl phenol, or a 1-(alkylsulfonyl)-4,5,-dihydro-1H-imidazole.
  • a compound that antagonizes MDM2/p53 or MDM4/p53 complex and that is an imidazole, an imidazolidine, a ⁇ -lactam, a tetrahydroquinoline, a 2-aminomethyl phenol, or a 1-(alkylsulfonyl)-4,5,-dihydro-1H-imidazole.
  • an imidazole an imidazolidine
  • a ⁇ -lactam a tetrahydroquinoline
  • 2-aminomethyl phenol or a 1-(alkylsulfonyl)-4,5,-dihydro-1H-imidazole.
  • Illustrative of such a compound is one that conforms to formula I
  • R1 is optionally substituted (C 3 -C 8 )aryl, (C 3 -C 8 )heterocycloalkyl, (C 3 -C 8 )heteroaryl, (C 1 -C 6 )alkyl(C 3 -C 8 )aryl, (C 3 -C 8 )aryl(C 1 -C 6 )alkyl, optionally substituted benzyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkyl and (C 3 -C 8 )cycloalkyl;
  • R2 is optionally substituted (C 3 -C 8 )aryl, optionally substituted (C 3 -C 8 )heteroaryl, optionally substituted (C 3 -C 8 )heterocycloalkyl, (C 3 -C 8 )heteroaryl(C 1 -C 6 )alkyl and (C 3 -C 8 )heterocyclo
  • R1 is straight or branched optionally substituted (C 1 -C 8 )alkyl, optionally substituted (C 3 -C 8 )aryl, (C 1 -C 8 alkyl)-S—(C 1 -C 8 alkylene), aryl(C 1 -C 6 )alkylene, (C 3 -C 8 )aryl(C 1 -C 6 )alkyl, optionally substituted benzyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkylene, optionally substituted (C 3 -C 8 )aryl and (C 3 -C 8 )cycloalkyl;
  • R2 is optionally substituted (C 3 -C 8 )aryl, optionally substituted (C 3 -C 8 )heteroaryl, fused or unfused (C 3 -C 8 )heteroaryl;
  • R3 is optionally substituted (C 1 -C 8 )alky
  • FIG. 1 is a schematic representation that illustrates the sequence of steps involved in the identification and ranking of virtual library compounds capable of binding to a protein target of interest.
  • FIG. 2A shows picture of p53 peptide (stick representation) bound to MDM2.
  • FIG. 2B shows picture of p53 peptide (stick representation) bound to MDM4.
  • FIG. 3 is a graphical representation showing the position of the amino acid triad (F, W, L) in the binding pocket of p53.
  • FIG. 4 shows a 1 H- 15 N-HSQC 600 MHz spectra of MDM2 in the presence (red) and absence (blue) of MDM2 binder.
  • FIG. 5A shows the predicted orientation for an imidazole in the binding pocket of MDM2.
  • FIG. 5B shows the observed binding mode based on X-ray crystal data.
  • FIG. 6 shows the predicted binding mode of azetidinone scaffold (light blue sticks) to MDM2. An overlap of nutlin-3 (green sticks) is shown.
  • FIG. 7 shows the proposed binding mode of tetrahydroquinoline scaffold to MDM2.
  • FIG. 8 shows the proposed binding mode of 1-alkylsulfonyl imidazolidines to MDM4.
  • Alkyl refers to a straight or branched chain, saturated hydrocarbon having the indicated number of carbon atoms.
  • (C 1 -C 6 )alkyl is meant to include, but is not limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, and neohexyl.
  • An alkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein throughout.
  • aryl refers to a 6- to 14-membered monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring system. Examples of an aryl group include phenyl and naphthyl. An aryl group can be unsubstituted or optionally substituted with one or more substituents as described herein throughout.
  • Cycloalkyl denotes a 3- to 14-membered saturated or unsaturated non-aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring system. Included in this class are cycloalkyl groups which are fused to a benzene ring.
  • heteroaryl refers to an aromatic heterocycle ring of 5 to 14 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including monocyclic, bicyclic, and tricyclic ring systems.
  • heteroaryls are triazolyl, oxadiazolyl, pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, pyrimidyl, azepinyl, oxepinyl, quinoxalinyl and oxazolyl.
  • a heteroaryl group can be unsubstituted or optionally substituted with one or more substituents as described throughout.
  • heterocycle refers to 3- to 14-membered ring systems that are either saturated, unsaturated, or aromatic, and that contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, where the nitrogen and sulfur heteroatoms can be optionally oxidized and the nitrogen heteroatom can be optionally quaternized, including monocyclic, bicyclic, and tricyclic ring systems.
  • the bicyclic and tricyclic ring systems may encompass a heterocycle or heteroaryl fused to a benzene ring.
  • the heterocycle can be attached via any heteroatom or carbon atom.
  • Heterocycles include heteroaryls as defined above.
  • heterocycloalkyl by itself or combined with other terms, represents cyclic versions of “heteroalkyl.” Additionally, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
  • MCR multicomponent reaction chemistry
  • high resolution X-ray or NMR structural data from the Protein Data Bank was used to define the sequence of residues that are involved in protein-protein interactions.
  • structural data relating to enzyme-substrate complexes can also be used to identify the fragment of the substrate involved in binding to the active site of an enzyme.
  • This information is then imported into a database containing MCR scaffolds to generate a virtual library of compounds that incorporate the salient feature of the fragment identified using structural data.
  • This virtual library then is docked into the high-resolution structure of the protein target of interest and the highest ranking virtual hits are inspected manually for structural consistency and energy requirements to binding. This allows the generation of a list of the most promising compounds that are synthesized in the lab and screened for activity ( FIG. 1 ).
  • FIGS. 2A and 2B pictorially depict the interactions of the key residues of a 15-amino acid peptide fragment of p53 in the binding sites of MDM2 and MDM4 as deduced from the X-ray coordinates of a high-resolution crystal structure of the protein-peptide complex.
  • Analysis of the p53/MDM2 structural data revealed that the indole ring of tryptophan would be a suitable fragment for generating a virtual library using the database of MCR scaffolds that contain an indole ring. As seen in FIG.
  • the present invention provides a method for generating and screening virtual libraries based on 40 different MCRs having the indole fragment.
  • the inventive method comprises docking individual molecules from the virtual library into a high resolution structure of the MDM2 protein. Docking is carried out by maintaining the same positional constraints on the indole ring of the docked molecule to those for the indole side chain in the high resolution X-ray structure of MDM2-p53 peptide.
  • the compounds identified from docking experiments as potential inhibitors of MDM2-p53 interaction are then synthesized and tested for the inhibitory activity using an NMR-based binding assay.
  • NMR-based screen has many advantages. For example, this screening method allows for the rapid determination of an approximate K A for the small molecule inhibitors, with the possibility of obtaining a more accurate K A value at a later time by titrating the p53-MDM2 complex using increasing concentrations of the inhibitor of interest.
  • a second advantage of using this technique is that it allows identification of the binding site of the small molecule in the target protein by investigating the chemical shift perturbations that occur on binding. This information can then be used to further refine the chemical scaffold with an aim towards improving the affinity of the molecule for its target.
  • NMR-based screening yields valuable information about promiscuous inhibitors which act as false positives by precipitating the target protein through hydrophobic effects.
  • a secondary NMR based assay was used to determine the dissociation constant (K D ) of p53 from MDM2.
  • K D dissociation constant
  • Table 1 lists promising chemotypes that were identified as antagonists of the p53/MDM2 complex. As mentioned later in this application, some of the compounds showed a dose dependant up regulation of p53 in ex-vivo cell based assays with one particular compound capable of disrupting the p53/MDM2 complex in the NMR tube at a nanomolar concentration.
  • the compounds identified using MCR were then screened for the ability to bind MDM2 or MDM4 (K A ) (primary assay).
  • the molecules identified as binders of MDM2 or MDM4 by the primary assay are subsequently tested for their ability to disrupt the MDM2/p53-peptide complex (K D ) in a secondary assay.
  • further downstream assays involving screening using various cell lines (PC3, A549, MDAMB231) and determination of the growth inhibition constants may be performed for a select sub-set of molecules.
  • Western blot analysis of certain compounds is performed to determine p53, MDM2, and p21 content.
  • the claimed MCR predicted compounds having an imidazole scaffold to be particularly potent antagonists of MDM2 or MDM4/p53 interaction.
  • the p53 tryptophane mimicking indole has to be placed at position-5 of the imidazole ring.
  • Table 2 summarizes the different compounds synthesized in this regard and their respective K A values.
  • Scheme 1 graphically depicts the synthesis of for this family of compounds. Synthesis to assemble the imidazole scaffold was carried out using the van Leusen 3-component reaction (CR) of a Tosmic derivative, an aldehyde and a primary amine under basic conditions to give the 1, 4, 5 substituted imidazoles. See van Leusen, Org. React . (2003), 7.
  • CR van Leusen 3-component reaction
  • the derivatives synthesized using the above methodology had binding affinities for MDM2 in the ⁇ M range.
  • the imidazole family of compounds had at least a 5-10 fold weaker binding affinity for MDM4.
  • the accuracy of the predicted binding model was further tested by synthesizing a compound that was known to be too big to fit into the binding site of MDM2 as determined by the NMR. Molecules identified as potential binders by the NMR screen are then used as templates to improve the binding properties of the next generation of imidazole analogs. It was found using the methodology of the instant invention that introducing a substituent at position-2 of the imidazole ring would promote the lipophilicity as well as the water solubility of this family of compounds.
  • the claimed MCR method identified compounds having an imidazoline scaffold as potent antagonists of the p53/MDM2 or MDM4 interaction.
  • the imidazolidine derivates were synthesized using a three component reaction involving an isocyanide ester of an ⁇ -amino acid, an aldehyde and a primary amine as shown in Scheme 2 using a published method. See Bon, R. S., et al., Org. Lett . (2003), 5, 3759. The observed affinities for synthesized analogs were in the low ⁇ M range when diasteriomeric mixtures enriched in the syn isomer were used in the screen (Scheme 3).
  • ⁇ -lactams provide another scaffold for designing potent antagonists of the p53/MDM2 or MDM4 complex.
  • Compounds having the azetidinone scaffold were synthesized using a stereospecific Staudinger 3-CR method, involving an acylchloride, a primary amine and a ketone or an aldehyde as shown in Scheme 5. See Palomo, C., et al., Eur. J. Org. Chem . (1999), 8, 3223. The results from docking studies revealed that substituents at positions 1, 3 and 4 of the ⁇ -lactam ring would mimic the side chains of the F, W and L amino acids of p53.
  • FIG. 6 shows a representation for the predicted binding mode for the azetidione scaffold to MDM2. Also depicted is an overlay of the known antagonist Nutlin-3. As seen in FIG. 6 , there is a remarkable overlap between the azetidione and Nutlin-3 structures. Based on the predicted binding model, derivatives at positions 3- and 4- of the azetidione scaffold were predicted to increase affinity and water solubility. The affinity for some representative examples of this family of compounds are provided in Scheme 6.
  • the present invention allows the synthesis and testing of tetrahydroquinoline analogs as inhibitors of p53/MDM complex.
  • a published procedure involving a three component reaction system was used for stereospecific synthesis of syn-2,4-disubstituted tetrahydroquinolines as shown in Scheme 7. See Kiselyov, A. S., et. al., Tetrahedron (1998), 54, 5089.
  • FIG. 7 shows the predicted binding of the disubstituted tetrahydroquinolines to the active site of MDM2, while Scheme 8 shows some representative examples. Based on the predicted binding mode and results from screens involving some key derivatives a repertoire of analogs will be made and tested. Of particular interest is the ease for derivatizing this scaffold at the reactive secondary amine, which also promotes the water solubility for this family of compounds.
  • 2-aminomethyl phenols are scaffolds for designing MDM2-p53 and MDM4-p53 complex inhibitors.
  • the target scaffold is synthesized using the Betti reaction that involves a reaction between a phenol, an aldehyde and a primary or secondary amine as depicted in Scheme 9. Some representative members for this family of compounds are shown in Scheme 10, along with their respective binding affinities for MDM2 and MDM4.
  • the 1-(Alkylsulfonyl)-4,5-dihydro-1H-imidazoles analogous to scaffold II are scaffolds for designing MDM2/p53 and MDM4/p53 complex inhibitors.
  • the 1-alkysulfonylated imidazoles can be synthesized from the reaction of N-sulfonylated Schiff bases with isocyanates (Scheme 11). See Lee et al., Tett. Lett . (2003), 44, 1231-1234. Scaffold VI differs from scaffold II by the sharper angle between the imidazoline ring plane and the residue at 1-position. According to the proposed binding model ( FIG. 8 ) it was predicted that scaffold VI would be especially useful for binding to MDM4 where the p53 leucine binding site is dramatically downsized as compared to MDM2 ( FIG. 2 ).
  • the p53 tumor suppressor is a central element for regulation of cell cycle progression, DNA repair, and apoptosis and is an attractive cancer therapeutic target because its tumor suppressor activity can be stimulated to inhibit the growth of tumor cells.
  • the p53 gene is mutated in ⁇ 50% of all human cancers. The remaining cancers retain wild-type p53 but the p53 pathway is inactivated or impaired through the interaction with negative regulators.
  • a known negative regulator of p53 is MDM2.
  • MDM4 also has been recognized as an equally important, negative p53 regulator. Fluorescence in situ hybridization and immunohistochemistry studies reveal an increased MDMX copy number in ⁇ 65% of human retinoblastomas, with MDM2 being amplified in an additional 10% of these tumors that exclusively have wild-type p53.
  • mice Both MDM2 and MDM4 proteins cooperate in inactivation of p53.
  • restoring p53 activity can halt the growth of cancerous tumors in mice, and in some cases, even cause tumors to disappear.
  • Two groups constructed genetically engineered mice with an inducible p53 gene and oncogenic mutations that facilitate cancer development (lymphoma and sarcoma). After the mice developed tumors, the p53 gene was turned on, which initiated apoptosis and resulted in the shrinkage of the tumors.
  • Gendicine another adenoviral vector for p53
  • HNSCC head-and-neck squamous cell carcinoma
  • MDM2 and MDM4 are highly promising targets to fight cancer.
  • Each of the scaffolds shown below can be made by conventional synthesis.
  • the underlying chemistry generally, is straightforward to perform and does not require an inert gas atmosphere or dry conditions.
  • Certain scaffolds are produced as diastereomeric mixtures and were separated by well-known chiral chromatography or crystallization techniques.
  • Compounds can be made on a 50-100 mg scale for analytical (NMR, HPLC-MS, HR-MS) and screening purposes.
  • the first intermediates can be prepared in larger quantities, e.g., 200-300 mg.
  • Derivatives that show a high affinity for the protein were produced in larger quantities for xenograft screening. It is preferable that compounds of the invention have ⁇ 95% purity as shown by HPLC, using UV/ELSC/TIC detectors and 1 H-NMR, for example.
  • the affinities and water solubility can be refined for classes of identified antagonists of p53/MDM2/MDM4 binding.
  • Such compounds can be optimized by individually, synthesizing rather small libraries of 3-10 compounds per round.
  • the chemistry tasks should be flexible to a certain degree, since the optimization process involves design and synthesis of compounds, screening of the compounds, and designing of a new round of compounds based on the results.
  • Illustrative in this regard are three scaffolds, whose affinities for MDM2 and MDM4 were increased as described in greater detail below.
  • the double digit micro-molar binding affinity for the imidazole family of compounds was increased by at least three routes could be used to increase the affinity.
  • the first approach seeks to gain an additional hydrogen bonding site in the Phe binding pocket where an exposed backbone carbonyl of Asn 72 seems to be approachable.
  • the inventors have determined that this carbonyl group can be addressed by an appropriately placed substituent at position-1 of the imidazole (the amine component). Accordingly, compounds such as 3-aminomethyl phenol, 3-aminomethyl aniline, 3-aminomethyl-cyclohexylamine, 3-aminomethyl-piperidine or similar compounds are disclosed as suitable precursors to approach this additional hydrogen bonding.
  • a second approach for increasing affinity entails introducing substituents in the 2-position of the imidazole ring to gain additional van der Waals interaction and even water solubility.
  • a substituent in the 2-position would mimic the interactions of the Leu (FSDLWK L L) in p53, which contributes additional van der Waals interactions in addition to FWL.
  • Optimization of compounds that belong to this family was carried out as shown in Scheme 1.
  • Table 2 lists representative analogs that were synthesized with their GI50 values against HCT116 cells in culture. The chemistry to accomplish substitution at position-2 of the immidazole ring would involve generation of the carbanion using LDA and subsequent alkylation with iminium salts or other alkylating agents.
  • a third approach for optimizing the affinity of this family of compounds involves substitutions at 5-position of the imidazole ring.
  • the starting material for this position according to one suitable synthetic route, are appropriately substituted p-toluene sulfonamides (Tosmic).
  • Tosmic p-toluene sulfonamides
  • several substituted phenyl Tosmics can be prepared and transformed to smaller libraries of imidazoles, according to the van Leusen chemistry as shown in Scheme 1.
  • Preferred antagonists belonging to this chemotype have binding affinities (K A ) in the nM range.
  • K A binding affinities
  • a straightforward approach for the facile synthesis of anatagonists is to derivatize the carboxylic acid ester site.
  • the carbonyl group of the ester is appropriately positioned for interaction with the Arg-residue of the p53 peptide. Modifications at this position of the imidazolidine scaffold could be used to increase the binding affinity as well as the water solubility of this class of molecules.
  • the present invention provides a method for introducing a variety of lipophilic and water solubilizing groups, e.g., ethyl, propyl, cyclo-propylmethyl, 2-hydroxyethyl, 2-morpholinoethyl, 2-(hydroxymethyl)ethyl, 2-piperidinylethyl, 2-amino(N,N-diethyl)ethyl, and other similar groups into the imidazolidine scaffold.
  • substituents at imidazolidine 1-position could be used to probe the above-mentioned hydrogen bonding interaction between the carbonyl group of Asn 72 and the bound analog. Optimization of compounds that belong to this family was carried out as shown in Scheme 12. Table 3 lists representative analogs that were synthesized with their GI50 values against HCT116 cells in culture. Further optimization at position-4 could also be done by the synthetic method of Scheme 2.
  • NMR-based docking and preliminary binding assays have shown that the 1-(Alkylsulfonyl)-4,5-dihydro-1H-imidazole scaffold could be used to develop selective and dual-active MDM2/4 antagonists, in accordance with the invention.
  • a suitable route for optimizing this scaffold are depicted in Schemes 11 and 13.
  • the primary sulfonamides used for synthesizing the 1-(Alkylsulfonyl) imidazole analogs can be synthesized from commercially available sulfonylchlorides using a published procedure.
  • R4 R5 is H, alkyl, cycloalkyl;
  • R6 R7 is H, alkyl, cycloalkyl; and
  • X O, N

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US12/106,280 2007-04-20 2008-04-19 Selective and dual-action p53/MDM2/MDM4 antagonists Active 2030-12-16 US8163789B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/106,280 US8163789B2 (en) 2007-04-20 2008-04-19 Selective and dual-action p53/MDM2/MDM4 antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90790207P 2007-04-20 2007-04-20
US96051607P 2007-10-02 2007-10-02
US12/106,280 US8163789B2 (en) 2007-04-20 2008-04-19 Selective and dual-action p53/MDM2/MDM4 antagonists

Publications (2)

Publication Number Publication Date
US20080280769A1 US20080280769A1 (en) 2008-11-13
US8163789B2 true US8163789B2 (en) 2012-04-24

Family

ID=39671481

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/106,280 Active 2030-12-16 US8163789B2 (en) 2007-04-20 2008-04-19 Selective and dual-action p53/MDM2/MDM4 antagonists

Country Status (2)

Country Link
US (1) US8163789B2 (fr)
WO (1) WO2008130614A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365833B2 (en) 2013-09-30 2016-06-14 Samsung Electronics Co., Ltd. Leucine zipper variant and use thereof
US9902758B2 (en) 2015-04-23 2018-02-27 Samsung Electronics Co., Ltd. Three-helix bundle protein and use thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011106650A2 (fr) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nouveaux antagonistes de p53-mdm2/p53-mdm4 pour traiter une maladie de prolifération
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
AU2011299551A1 (en) * 2010-09-08 2013-03-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P53-Mdm2 antagonists
FR2967072B1 (fr) * 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CA2817568A1 (fr) * 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Therapies et diagnostics du cancer
UA109464C2 (uk) 2010-11-12 2015-08-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи mdm2
CA2835422C (fr) 2011-05-11 2016-10-11 The Regents Of The University Of Michigan Agonistes de mdm2 consistant en spiro-oxindoles
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (fr) 2013-02-28 2017-09-27 Amgen Inc. Inhibiteur mdm2 dérivé de l'acide benzoïque pour le traitement du cancer
EP2970237B1 (fr) 2013-03-14 2017-09-27 Amgen Inc. Composés morpholinone d'acide hétéroaryle utilisés comme inhibiteurs de mdm2 pour le traitement du cancer
CA2913697A1 (fr) 2013-05-27 2014-12-04 Novartis Ag Derives imidazopyrrolidinone et leur utilisation dans le traitement de maladies
BR112015029353A2 (pt) 2013-05-28 2017-07-25 Novartis Ag derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
CN105263934B (zh) 2013-05-28 2017-09-08 诺华股份有限公司 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
US10053498B2 (en) 2014-11-21 2018-08-21 University of the Sciences of Philadelphia Compositions comprising serum albumin and p53 peptides fusion proteins
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
WO2024240858A1 (fr) 2023-05-23 2024-11-28 Valerio Therapeutics Molécules protac dirigées contre un système de réparation de dommages à l'adn et leurs utilisations

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Alexander Domling, "Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry", Chem. Rev. 2006, 106, 17-89.
Alexander S. Kiselyov et al., "Solid Support Synthesis of Polysubstituted Tetrahydro-quinolines via Three-Component Condensation Catalyzed by Yb(OTf)3.", Tetrahedron 54 (1998) 5089-5096.
Claudio Palomo et al., "Asymmetric Synthesis of beta-Lactams by Staudinger Ketene-Imine Cycloaddition Reaction", Eur. J. Org. Chem. 1999, 3223-3235.
Claudio Palomo et al., "Asymmetric Synthesis of β-Lactams by Staudinger Ketene-Imine Cycloaddition Reaction", Eur. J. Org. Chem. 1999, 3223-3235.
Franck Toledo et al., "Regulationg the p53 pathway: in vitro hypotheses, in vivo veritas", Nature Reviews, Cancer, vol. 6, Dec. 2006, pp. 909-923.
Gelens et al, Molecular Diversity (2006), vol. 10, pp. 17-22. *
International Search Report PCT/US2008/004993.
Ka Young Lee et al., "A practical synthesis of N-tosylimines of arylaidehydes", Tetrahedron Letters 44, (2003) 1231-1234.
Lyubomir T. Vassilev et al., "In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2", Science, vol. 303, Feb. 6, 2004, pp. 844-848.
Robin S. Bon et al., "Novel Multicomponent Reaction for the Combinatorial Synthesis of 2-Imidazolines", Organic Letters, vol. 5, No. 20, 2003, pp. 3759-3762.
Walfrido Antuch et al., "Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold", Bioorganic & Medicinal Chemistry Letters 16 (2006) 1740-1743.
Walfrido Antuch et al., "Design and modular parallel synthesis of a MCR derived α-helix mimetic protein—protein interaction inhibitor scaffold", Bioorganic & Medicinal Chemistry Letters 16 (2006) 1740-1743.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365833B2 (en) 2013-09-30 2016-06-14 Samsung Electronics Co., Ltd. Leucine zipper variant and use thereof
US9902758B2 (en) 2015-04-23 2018-02-27 Samsung Electronics Co., Ltd. Three-helix bundle protein and use thereof

Also Published As

Publication number Publication date
US20080280769A1 (en) 2008-11-13
WO2008130614A3 (fr) 2008-12-24
WO2008130614A2 (fr) 2008-10-30

Similar Documents

Publication Publication Date Title
US8163789B2 (en) Selective and dual-action p53/MDM2/MDM4 antagonists
Poyurovsky et al. The C terminus of p53 binds the N-terminal domain of MDM2
Stevens et al. Integrated direct-to-biology platform for the nanoscale synthesis and biological evaluation of PROTACs
US20170131278A1 (en) Method for screening inhibitors of ras
Zhou et al. Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers
EP2814821B1 (fr) Contrôle de l'expression génique induite par l'hypoxie avec des mimétiques hélicoïdaux non peptidiques d'oligo-oxopipérazine
Kita et al. Interactions of the antitumor macrolide aplyronine A with actin and actin-related proteins established by its versatile photoaffinity derivatives
HUE032187T2 (en) Use of acetylated tubulin as a biomarker for response to furazanobenzimidazoles
Ban et al. Identification of targets of the HIF-1 inhibitor IDF-11774 using alkyne-conjugated photoaffinity probes
He et al. ATNC: versatile nanobody chimeras for autophagic degradation of intracellular unligandable and undruggable proteins
US20240132485A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
US11560359B2 (en) Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression
US20250144099A1 (en) Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
Zhou et al. Exploring degradation of intrinsically disordered protein yes-associated protein induced by proteolysis TArgeting chimeras
Zhou et al. Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents
US20240002458A1 (en) Novel vhl small molecule probes
US20230044407A1 (en) Targeting mb2 of the myc oncogene and its interaction with trrap in cancer
US20250066325A1 (en) Directed degron molecules and applications thereof
He et al. An enhanced functional interrogation/manipulation of intracellular signaling pathways with the peptide ‘stapling’technology
Wittenburg et al. Breaking Barriers in PROTAC Design: Improving Solubility of USP7-Targeting Degraders
Premnath et al. Development of inhibitors of protein-protein interactions through REPLACE: Application to the design and development non-atp competitive cdk inhibitors
Dilday Characterization of a Novel Hunk Inhibitor in HER2+ Breast Cancer
Baryyan New Kinase-Based Molecular Diagnostic Tools for Target Discovery, Live Imaging, and Drug Response Profiling in Cancer
US11964022B2 (en) Small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1
Wittenburg et al. Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOEMLING, ALEXANDER;REEL/FRAME:021200/0896

Effective date: 20080707

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 12